Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 10/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL640673 | 1.00 | CES2 (0.50) | CES2CES1KDM1ARECQLPLA2G7 | |
| SCHEMBL8281129 | 0.83 | KDM1A (0.50) | KDM1ARECQLRAB9ALMNAGFER | |
| SCHEMBL20580081 | 0.83 | KDM1A (0.68) | KDM1ARECQLLMNA | |
| SCHEMBL14738905 | 0.83 | KDM1A (0.50) | KDM1ARECQLRAB9ALMNAGFER | |
| SCHEMBL2772394 | 0.83 | KDM1A (0.68) | KDM1ARECQLLMNA | |
| SCHEMBL16242452 | 0.83 | HDAC1 (0.55) | KDM1ARECQLRAB9ALMNAGFER | |
| SCHEMBL16242453 | 0.83 | HDAC1 (0.55) | KDM1ARECQLRAB9ALMNAGFER | |
| SCHEMBL25384548 | 0.82 | KDM1A (0.45) | KDM1ARECQLLMNAGFERKMT2A | |
| SCHEMBL22394821 | 0.82 | KDM1A (0.45) | KDM1ARECQLLMNAGFERKMT2A | |
| SCHEMBL8221010 | 0.82 | KDM1A (0.45) | KDM1ARECQLRAB9ALMNAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275723-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-15 | — | — | US | disclosed |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-05 | — | — | US | disclosed |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| US-11970486-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-30 | — | — | US | disclosed |
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-18 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| CN-114269340-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2009148452-A1 | NOVEL 1,2,4 OXADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090198057-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INCORPORATED | 2009-08-06 | — | — | US | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | disclosed |
| US-6034106-A | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity | MERCK & CO., INC. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0906310-A4 | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE -g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO INC (US) | 1999-09-01 | — | — | EP | disclosed |
| EP-0906310-A1 | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997046556-A1 | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | CES2 124/4885CES1 1485/4885KDM1A 4113/4885 |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | CES2 124/4885CES1 1485/4885KDM1A 4113/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | CES2 124/4885CES1 1485/4885KDM1A 4113/4885 |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | CES2 124/4885CES1 1485/4885KDM1A 4113/4885 |
| US-20090198057-A1 | Certain Chemical Entities, Compositions, and Methods | MYLK, MYH2, MYH10 | CES2 1325/4885CES1 1407/4885KDM1A 2098/4885 |
| US-12275723-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | CES2 124/4885CES1 1485/4885KDM1A 4113/4885 |
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | OXA1L, CYP11B2, CYP1B1 | CES2 248/4885CES1 571/4885KDM1A 2088/4885 |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | CHRNA4, CHRNB4, CHRNA5 | CES2 959/4885CES1 2716/4885KDM1A 2455/4885 |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | CES2 1241/4885CES1 1740/4885KDM1A 972/4885 |
| US-11970486-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | CES2 124/4885CES1 1485/4885KDM1A 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.